Reata Pharmaceuticals, Inc.
Simbol: RETA
NASDAQ
172.36
USDTržna cena danes
-89.3629
Razmerje P/E
0.0000
Razmerje PEG
6.57B
Kapaciteta MRK
- 0.00%
Donos DIV
Reata Pharmaceuticals, Inc. (RETA) Finančni izkazi
Bilanca stanja
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1474.56 | 387.5 | 590.3 | 818.1 | ||||||||||
balance-sheet.row.short-term-investments | 1266.55 | 345.2 | 0 | 0 | ||||||||||
balance-sheet.row.net-receivables | 16.95 | 0 | 0 | 22.2 | ||||||||||
balance-sheet.row.inventory | 8.65 | 0 | 0 | -22.2 | ||||||||||
balance-sheet.row.other-current-assets | 77.1 | 10.3 | 6.2 | 29.2 | ||||||||||
balance-sheet.row.total-current-assets | 1577.27 | 397.8 | 596.5 | 847.3 | ||||||||||
balance-sheet.row.property-plant-equipment-net | 459.6 | 116.4 | 138.4 | 4.9 | ||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-non-current-assets | 17.44 | 0.3 | 0.2 | 5.3 | ||||||||||
balance-sheet.row.total-non-current-assets | 477.04 | 116.7 | 138.5 | 10.3 | ||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-assets | 2054.3 | 514.5 | 735 | 857.6 | ||||||||||
balance-sheet.row.account-payables | 60.53 | 18.7 | 13.5 | 4.8 | ||||||||||
balance-sheet.row.short-term-debt | 13.07 | 2.2 | 3.1 | 87.5 | ||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-debt-total | 534.25 | 117.3 | 136 | 0 | ||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 4.7 | ||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||
balance-sheet.row.other-current-liab | 131.23 | 38.1 | 35.7 | 22.3 | ||||||||||
balance-sheet.row.total-non-current-liabilities | 1869.5 | 521.2 | 495 | 321 | ||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.capital-lease-obligations | 470.98 | 119.5 | 136 | 0 | ||||||||||
balance-sheet.row.total-liab | 2158.86 | 580.2 | 549 | 440.2 | ||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.common-stock | 0.15 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.retained-earnings | -6223.86 | -1567.5 | -1255.6 | -958.2 | ||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-total-stockholders-equity | 4566.18 | 1501.8 | 0 | 0 | ||||||||||
balance-sheet.row.total-stockholders-equity | -1657.54 | -65.7 | -1255.6 | -958.2 | ||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 501.33 | 514.5 | -706.6 | -518.1 | ||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-equity | -1657.54 | -65.7 | -1255.6 | -958.2 | ||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 501.33 | - | - | - | ||||||||||
Total Investments | 1266.55 | 345.2 | 0 | 0 | ||||||||||
balance-sheet.row.total-debt | 544.11 | 119.5 | 136 | 0 | ||||||||||
balance-sheet.row.net-debt | 336.1 | 77.2 | -454.2 | -818.1 |
Izkaz denarnih tokov
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -87.62 | -311.9 | -297.4 | -247.8 | ||||||||||
cash-flows.row.depreciation-and-amortization | 1.13 | 1.1 | 1.2 | 1.1 | ||||||||||
cash-flows.row.deferred-income-tax | -291.96 | 0 | 0 | 11.2 | ||||||||||
cash-flows.row.stock-based-compensation | 87.84 | 58.7 | 56.8 | 57.6 | ||||||||||
cash-flows.row.change-in-working-capital | 7.84 | 9.3 | -49.6 | -172.7 | ||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.inventory | -13.28 | 0 | 0 | 0 | ||||||||||
cash-flows.row.account-payables | 11.97 | 5.2 | 8.7 | 2.9 | ||||||||||
cash-flows.row.other-working-capital | 9.16 | 4.1 | -58.3 | -175.6 | ||||||||||
cash-flows.row.other-non-cash-items | 34.44 | 38.5 | 53.3 | 28.1 | ||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -248.34 | 0 | 0 | 0 | ||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -1.12 | -3.3 | -1.3 | -0.9 | ||||||||||
cash-flows.row.acquisitions-net | 75 | 0 | 0 | 0 | ||||||||||
cash-flows.row.purchases-of-investments | -631.88 | -661.9 | 0 | 0 | ||||||||||
cash-flows.row.sales-maturities-of-investments | 617.42 | 320 | 0 | 0 | ||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 59.42 | -345.2 | -1.3 | -0.9 | ||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | -167.2 | ||||||||||
cash-flows.row.common-stock-issued | 222.73 | 0 | 333.3 | 333.3 | ||||||||||
cash-flows.row.common-stock-repurchased | 22.65 | 0 | 0 | 0 | ||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||
cash-flows.row.other-financing-activites | -231.54 | 1.5 | -324.1 | 311 | ||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 90.61 | 1.5 | 9.1 | 477.1 | ||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 167.98 | 0 | 0 | 0 | ||||||||||
cash-flows.row.net-change-in-cash | -98.31 | -547.9 | -227.9 | 153.8 | ||||||||||
cash-flows.row.cash-at-end-of-period | 208.01 | 42.3 | 590.3 | 818.1 | ||||||||||
cash-flows.row.cash-at-beginning-of-period | 306.32 | 590.3 | 818.1 | 664.3 | ||||||||||
cash-flows.row.operating-cash-flow | -248.34 | -204.3 | -235.7 | -322.3 | ||||||||||
cash-flows.row.capital-expenditure | -1.12 | -3.3 | -1.3 | -0.9 | ||||||||||
cash-flows.row.free-cash-flow | -249.46 | -207.5 | -237 | -323.3 |
Vrstica izkaza poslovnega izida
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 24.39 | 2.2 | 11.5 | 9 | ||||||||||
income-statement-row.row.cost-of-revenue | 0.85 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.gross-profit | 23.55 | 2.2 | 11.5 | 9 | ||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.research-development | 203.31 | - | - | - | ||||||||||
income-statement-row.row.selling-general-administrative | 114.18 | - | - | - | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.other-expenses | 0.73 | 1.1 | 1.2 | 1.1 | ||||||||||
income-statement-row.row.operating-expenses | 364.3 | 280.3 | 256.2 | 235.3 | ||||||||||
income-statement-row.row.cost-and-expenses | 365.15 | 280.3 | 256.2 | 235.3 | ||||||||||
income-statement-row.row.interest-income | 0 | 6 | 0.2 | 0 | ||||||||||
income-statement-row.row.interest-expense | 40.61 | 41.8 | 53.3 | 36.8 | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.total-other-income-expensenet | 253.97 | -41.8 | -53.1 | -43.9 | ||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.other-operating-expenses | 0.73 | 1.1 | 1.2 | 1.1 | ||||||||||
income-statement-row.row.total-operating-expenses | 253.97 | -41.8 | -53.1 | -43.9 | ||||||||||
income-statement-row.row.interest-expense | 40.61 | 41.8 | 53.3 | 36.8 | ||||||||||
income-statement-row.row.depreciation-and-amortization | 1.13 | 1.1 | 1.2 | 1.1 | ||||||||||
income-statement-row.row.ebitda-caps | -332.65 | - | - | - | ||||||||||
income-statement-row.row.operating-income | -59.48 | -270.2 | -244.7 | -226.3 | ||||||||||
income-statement-row.row.income-before-tax | -87.68 | -311.9 | -297.8 | -270.2 | ||||||||||
income-statement-row.row.income-tax-expense | 0.25 | 0 | -0.5 | -22.5 | ||||||||||
income-statement-row.row.net-income | -80.06 | -311.9 | -297.4 | -247.8 |
Pogosto zastavljeno vprašanje
Kaj je Reata Pharmaceuticals, Inc. (RETA) skupna sredstva?
Reata Pharmaceuticals, Inc. (RETA) skupna sredstva so 514491000.000.
Kakšen je letni prihodek podjetja?
Letni prihodki so 22941000.000.
Kolikšna je stopnja dobička podjetja?
Dobiček podjetja je 0.965.
Kakšen je prosti denarni tok podjetja?
Prosti denarni tok je -6.010.
Kolikšna je neto stopnja dobička podjetja?
Čista stopnja dobička je -3.282.
Kolikšni so skupni prihodki podjetja?
Celotni prihodki so -2.438.
Kaj je Reata Pharmaceuticals, Inc. (RETA) čisti dobiček (čisti dobiček)?
Čisti dobiček (čisti prihodek) je -311901000.000.
Kolikšen je skupni dolg podjetja?
Skupni dolg je 119464000.000.
Kolikšni so stroški poslovanja?
Stroški poslovanja so 280250000.000.
Kolikšno je število denarnih sredstev podjetja?
Denarna sredstva podjetja so 48843000.000.